Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lupin Limited ( (IN:LUPIN) ) has shared an announcement.
Lupin Limited has launched Risperidone for extended-release injectable suspension in the U.S., marking the first product from its proprietary PrecisionSphere™ platform. This launch, supported by a 180-day CGT exclusivity, underscores Lupin’s commitment to expanding its portfolio of complex injectables and enhancing global access to advanced long-acting treatments. The product is bioequivalent to Risperdal Consta® and is used for treating schizophrenia and bipolar I disorder, with significant market potential in the U.S.
More about Lupin Limited
Lupin Limited is a global pharmaceutical company known for its focus on developing complex generics and specialty products. The company operates in the healthcare industry, with a strong emphasis on creating innovative drug delivery systems, such as its proprietary long-acting injectable platform, PrecisionSphere™.
Average Trading Volume: 20,891
Technical Sentiment Signal: Buy
Current Market Cap: 929.9B INR
Find detailed analytics on LUPIN stock on TipRanks’ Stock Analysis page.